Variable Interest Entity

3 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company has substantial governance rights over Profarma Distribuidora de Produtos Farmacêuticos S.A. (“Profarma”) that allow it to direct the activities that significantly impact Profarma’s economic performance. As such, the Company consolidates the operating results of Profarma in its consolidated financial statements. The Company is not obligated to provide future financial support to Profarma.

The following assets and liabilities of Profarma are included in the Company’s Consolidated Balance Sheets:


(in thousands)	December 31, 2025		September 30, 2025
Cash and cash equivalents	$	27,155	$	70,796
Accounts receivables, net	304,158		260,759
Inventories	313,575		303,480
Prepaid expenses and other	54,438		55,981
Property and equipment, net	69,570		65,410
Other intangible assets	53,126		53,861
Other long-term assets	96,671		99,519
Total assets	$	918,693	$	909,806

Accounts payable	$	400,242	$	349,876
Accrued expenses and other	77,819		71,383
Short-term debt	51,769		116,361
Long-term debt	98,772		65,390
Deferred income taxes	11,386		11,986
Other long-term liabilities	72,331		75,132
Total liabilities	$	712,319	$	690,128

Profarma’s assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.

Cencora, Inc. 10-Q